Biohope, a Spanish biotechnological company that investigates, develops and commercializes unique medical solutions in the field of chronic inflammation, engaged The Harel Group to search for strategic partners to commercialize Immunobiogram in Japan and Brazil.

Biohope engaged The Harel Group, a business development advisory firm,  to support its global commercialization strategy with initial focus on Japan and Brazil. By entering into this collaboration, Biohope will leverage The Harel Group’s expansive global network of hundreds of life science companies in the US, Europe, Japan, Latin America, the Middle East, Africa, and Asia Pacific.

Biohope is dedicated to the development of precision medicine in-vitro diagnostic (IVD) tools for chronic inflammatory conditions to improve clinical outcomes by allowing the personalization and optimization of current and future treatments. Driven by innovation, Immunobiogram is a novel, unique and patented technology platform which provides physicians with important information to optimize the use of specific drugs and dosages of immunosuppressive therapies for individual patients.

IMBG-Renal Transplant is the first product ready for commercialization. In a multi-national clinical study performed in Europe and in the US, the effectiveness of IMBG-Renal Transplant was demonstrated. Equally important, it suggested, in a pharmacoeconomic model study, that routine use of IMBG-Renal Transplant in patients one year after their renal transplant would reduce the risk of renal graft failure and adverse events associated with immunosuppressive therapies with considerable savings for the payers.

Commercial launch of IMBG-Renal Transplant in Europe will begin upon the receipt of CE mark anticipated in Q2 2020. In the US, it will be commercialized in the form of Laboratory Developed Test in the first half of 2021. On the research front, the Immunobiogram technology will further be developed for use in other organ transplants and autoimmune diseases.

Biohope engaged The Harel Group, a business development advisory firm, founded and led by Jacob Harel, to support its global commercialization strategy with initial focus on Japan and Brazil. By entering into this collaboration, Biohope will leverage The Harel Group’s expansive global network of hundreds of life science companies in the US, Europe, Japan, Latin America, the Middle East, Africa, and Asia Pacific.

“Biohope is an energetic and innovative company committed to becoming a global pioneer to transform the management of chronic inflammation into precision medicine. It gives hope for the best health outcomes to patients who have undergone organ transplantation or suffer from autoimmune diseases,” stated Jacob Harel, President of The Harel Group. “We look forward to collaborating with Biohope as it steps into actualizing its mission.”

“We are pleased to be working with The Harel Group to support our mission to provide innovative, first in class, practical solutions that significantly improve clinical outcomes of autoimmune-related conditions. As a result, patients, physicians and health care systems will all benefit,” said Isabel Portero, Founder and CEO of Biohope. “The Harel Group is comprised of highly experienced professionals in the life science industry with a unique international and commercial expertise, which will serve our business objectives well.”